BCL2L1 and plasma cell myeloma: Overexpression of Bcl-xL has been reported in the majority of various hematologic malignancies, including Burkitt’s lymphoma (BL), diffuse large B cell lymphoma (DLBCL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM) [41,42].